Member Info for crumbs

I feel like saying at bloody last! But instead, feel all wooooo hooo! :) ... The potential of this trial can IMHO not be overstated it could change Immuno oncology forever ... never mind what it could do to scancell.... hopefully we get some decent media around this and off we go ... all the best to those about to be a part of this trial they above all others need this novel therapeutic proving itself as game changer -well done team scancell I bet Lindy is over the moon and we may get to hear from her soon... that 3 platforms having products in clinical trial already... yesss

AB modi 1 needs to be getting over the line first... I'm wondering if that one will be by 2030 :)
Really though a lot going on and we know there has always been industry interest in moditope right from the start and the BOD conversations around spinning it into its own company... so you never know moditope could surprise but not surprise with the first real commercial action even... We do sorely need an update though.

Having demonstrated that immunized transgenic mice expressing human HLA types show homocitrulline-specific immune responses, we next determined whether healthy human donors exhibit a repertoire for homocitrullinated peptides. For this we concentrated on the Vim116-135Hcit peptide.

PBMCs were isolated from 17 healthy donors and assessed for proliferative responses to homocitrullinated peptides. Donor details including HLA-types are shown in Table 2. Flow cytometry staining was used to assess CFSE proliferation in the CD4+ or CD8+ cell populations. Proliferation was assessed at day 10 post-stimulation as this timepoint showed clear peptide-induced proliferative responses. An example staining profile is shown in Figure 3A and additional example CFSE profiles for day 7 and day 10 are shown in Supplementary Figure 2. CFSE proliferation to the positive control PHA was seen in both the CD4 and CD8 populations, however, Vim116-135Hcit proliferation was predominantly seen in the CD4 population. Collated data from healthy donors is shown in Figure 3B whilst CD4 proliferative responses in individual healthy donors are shown in Figure 3Ci. In PBMCs from healthy donors, 15/17 showed CD4 T-cell proliferation in response to Vim116-135Hcit peptide. Across all donors, Vim116Hcit induced a significant increase in CD4 proliferation compared to media only (p<0.0001) (Figure 3Cii).

What are the odds of Scancell having Modi 2 in trial by 2040 ? :)))

Really though good work Berm and nice to see Scancell up early to retweet it from you
Hopefully some great news on the way here...... soooooooony sunakky soon!

Other possibles are trial design changes possibly relating to moditope preclinical data constantly coming in from research and how to get the best possible most likely to respond cohorts into a potential make or break game-changing potential trial... Or a partner is getting involved... i.e deal is coming Cliff always told me in emails modi1 very well could get a deal before it went into trial.... so I dunno most likely the NHS hold up though ....

Yes brilliant the IMF along with CEPI and Welcome Trust has just released this paper
file:///home/chronos/u-6e70dffff9d70843c36b44684ac18438d7d16f37/MyFiles/Downloads/wpiea2022068-print-pdf.pdf

Covid is going to be with us for a long long time with at least 4 different scenarios listed (they all include vacination)... D to be best avoided!

The best vaccines will come to the fore!

And that is the thing scancell is one of those shares that have game-changer RNS potential... multiple times... So whilst nothing has been valued all these posts about is the sp too high or too low are without substance it is down to fundamentals and personal risk/reward strategies ... I can't call the next RNS and neither can anyone else... I would like it to be modi1 going into trial... and ideally with an impressively named partner with more than mcap upfronts.... And yeah such RNS's are possible on multiple products of 4 platforms of a pipeline with pharma filling potential... I patiently nibble myself all the way towards a 400k holding :)

I think what we can say is CEPI are aware of Covidity and scancell are aware of CEPI and their funds ... and after that well who knows lol... the best thing we can take from it is Covidity (immunoBody) ticks all boxes and there are available funding options for Covidity...plus Covid isn't going anywhere fast and needs longer-term better vaccine solutions

Well, more fool you crackers... I've got £200 waiting on 4p.... Lindy better not mess it up by revealing some game-changer news on one of the multi hard to treat high-value targeting products of the 4 platforms pipelines!

All air bags same usual story on sp going down fundamentals remain here nothing has been valued at all scancell have even turned MAB deals down to add value the real key is to try to value the IP an IP with pharma filling potential....yes the timeline issues and understandable sentiment shifts to be expected but me I'm on way to owning 400k of shares...can wait for values to arrive....modi1 news got to be on its way

Not only wants but NEEDS oil production ramping up right now which makes COPL=a no brainer
MMS may well do an AM drag down making it a great buying op and blue pm....

Agree Chester it is a positive sign for how the trial is progressing with no safety issues remembering this not only means ImmunoBody but also Aividimab as well....of course, it would have been good to get this change sooner to up the recruitment but probably they needed this safety data to date ...anyways I expect the recruitment to speed up now considering the cash incentive and possibly 'needle free' attractively aspect too...Covid is going nowbere fast!... I stil havent knowing had it yet (3 vaxs) but most of my family have now... and hospital admissions are rising due to it ... the need for Covidty like vaxs remains crucial.... So todays RNS sure it was a very Scancell one of slow progress but it is progress we are getting there!.... next modi1 please!

Should know by now scancell do not do dates! :)

From the FT:
Finance, culture,talent why Europe struggles to commercialise its biotech expertise
https://www.ft.com/content/e95c5af8-e6ce-4625-8604-94af5d518ac0

Great to see BioNTech proactively using their covid vax funds to build a European based pharma but they too needed the US to do it...

Mine are in the bit below the bottom drawer where things go when they fall out the back where the spiders hang out and you have to poke around in the dark to find them again :))

Yeah from the cup of eternal optimism :) .... a modi 1 update is sorely needed even if it inconveniently misses out the $1billion upfront bit :)

Yes,modi1 trial or lack of is the frustration,I'm hoping the delay and tweak is down to the $1billion upfront with milestone payments partnership deal with pharma x that will come with the trial starting RNS :) can but dream but such assets with such potential do attract such deals

Website updated: 4 platforms 2 of Vaccines 2 of Antibodies....A pipeline that could potentially fill a pharma.....
https://www.scancell.co.uk/home

WTP well we can see with Nektars failing in combo therapeutic that BMS paid a cool $1 billion upfront plus big milestones and Nektar still maintained attractive commercial rights..... so those are the kinds of deals that can be done on a high-risk asset that has turned out to sadly not to live up to its potential......but that is the thing Nektar has managed to nail such big bucks deals not just with BMS but Merck and Lilly and others .....let us hope that missing part of our jigsaw is at this moment being put into place....Nektar did have an mcap of something like $1.5 billion and previously much much more till today when it is now half that ....

'The largest biotech licensing deal in history at the time of its inking in 2018 has now gone belly up and will cause Nektar Therapeutics to make "substantial changes" to its operations in the coming weeks after "very upsetting" results showing the drug bempegaldesleukin failed a phase 3 study that was testing it in combination with Bristol Myers Squibb's Opdivo.'
https://www.fiercebiotech.com/biotech/bms-nektar-opdivo-combo-therapy-fails-phase-3-upset-once-largest-licensing-deal-biotech

Just call Lindy....